BioAge Labs Inc (NASDAQ:BIOA) does about 664.66K shares in volume on a normal day but saw 930103 shares change hands in the recent trading day. The company now has a market cap of 146.98M USD. Its current market price is $4.10, marking a decrease of -0.97% compared to the previous close of $4.14. The 52 week high reached by this stock is $26.62 whilst the lowest price level in 52 weeks is $4.11. The script in recent trading has seen the stock touch a high of $45 and a low of $7.
BioAge Labs Inc (BIOA) has a 20-day trading average at $13.72 and the current price is -84.60% off the 52-week high compared with -0.24% distance from its 52-week low. If we look at the stock’s price movements over the week, volatility stands at 11.45%, which decreases to 8.86% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 21.30 to suggest the stock is oversold.
The consensus objective for the share price is $6.33, suggesting that the stock has a potential upside of 35.23% over the period. The median price target is 89.75% away from the current levels at $40.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 10, 2024 when Morgan Stanley downgraded the stock to “Underweight” and issued a price target of between $40 and $5. Jefferies also downgraded the stock to “Hold” from Buy on December 09, 2024 at a price target of $42-$7. Citigroup downgraded its price target at $45-$7.
The current price level is -70.11%, -78.38%, and -78.64% away from its SMA20, SMA50, and SMA200 respectively, with the BIOA price moving above the 50-day SMA on current market day. BioAge Labs Inc (BIOA) stock is down -8.28% over the week and -77.58% over the past month. Its price is -77.61% year-to-date.
The company’s next earnings report forecasts estimating quarterly EPS at -0.66 and -3.35 for whole year.
Its 12-month price target is $40. To reach the target analysts have set, the stock logically needs to grow 35.23 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $7, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $45.
Outstanding shares total 34.20M with insiders holding 3.62% of the shares and institutional holders owning 70.74% of the company’s common stock. Price to book ratio is 0.45.
